Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.
Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, Lanzafame H, Kasper S, Nader M, Kesch C, von Tresckow B, Hautzel H, Aigner C, Glas M, Stuschke M, Kümmel S, Harter P, Lugnier C, Uhl W, Hadaschik B, Grünwald V, Siveke JT, Herrmann K, Fendler WP. Hirmas N, et al. Among authors: herrmann k. J Nucl Med. 2024 Mar 1;65(3):372-378. doi: 10.2967/jnumed.123.266652. Epub 2024 Feb 8. J Nucl Med. 2024. PMID: 38331453
A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
Krafft U, Hadaschik BA, Lückerath K, Herrmann K. Krafft U, et al. Among authors: herrmann k. Eur Urol. 2024 Mar;85(3):227-228. doi: 10.1016/j.eururo.2023.09.022. Epub 2023 Oct 11. Eur Urol. 2024. PMID: 37833179 No abstract available.
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Guberina M, Pöttgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, Metzenmacher M, Aigner C, Bölükbas S, Gauler T, Eberhardt WEE, Forsting M, Herrmann K, Theegarten D, Darwiche K, Jendrossek V, Stuschke M, Schuler M. Guberina M, et al. Among authors: herrmann k. Cancers (Basel). 2024 Mar 17;16(6):1174. doi: 10.3390/cancers16061174. Cancers (Basel). 2024. PMID: 38539510 Free PMC article.
Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience.
Püllen L, Costa PF, Darr C, Hess J, Kesch C, Rehme C, Wahl M, Yirga L, Reis H, Szarvas T, van Leeuwen FWB, Herrmann K, Hadaschik BA, Tschirdewahn S, Krafft U. Püllen L, et al. Among authors: herrmann k. J Surg Oncol. 2024 Jun;129(7):1325-1331. doi: 10.1002/jso.27618. Epub 2024 Apr 7. J Surg Oncol. 2024. PMID: 38583145
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.
Gafita A, Martin AJ, Emmett L, Eiber M, Iravani A, Fendler WP, Buteau J, Sandhu S, Azad AA, Herrmann K, Stockler MR, Davis ID, Hofman MS. Gafita A, et al. Among authors: herrmann k. Eur Urol Oncol. 2024 Apr 6:S2588-9311(24)00085-3. doi: 10.1016/j.euo.2024.03.009. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38584037
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Flippot R, Telli T, Velev M, Fléchon A, De Vries-Brilland M, Turpin L, Bergman A, Turco F, Mahammedi H, Fendler WP, Giraudet AL, Josset Q, Montravers F, Vogel W, Gillessen S, Berardi Vilei S, Herrmann K, Kryza D, Paone G, Hadaschik B, Merlin C, Dufour PA, Bernard-Tessier A, Naoun N, Patrikidou A, Garcia C, Foulon S, Pagès A, Fizazi K. Flippot R, et al. Among authors: herrmann k. Eur Urol Oncol. 2024 Oct;7(5):1132-1140. doi: 10.1016/j.euo.2024.03.013. Epub 2024 Apr 24. Eur Urol Oncol. 2024. PMID: 38664139
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor O, Fanti S. Oprea-Lager DE, et al. Among authors: herrmann k. Eur Urol. 2024 Jan;85(1):49-60. doi: 10.1016/j.eururo.2023.09.003. Epub 2023 Sep 22. Eur Urol. 2024. PMID: 37743194 Free article.
Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation.
Lam M, Garin E, Haste P, Denys A, Geller B, Kappadath SC, Turkmen C, Sze DY, Alsuhaibani HS, Herrmann K, Maccauro M, Cantasdemir M, Dreher M, Fowers KD, Gates V, Salem R. Lam M, et al. Among authors: herrmann k. Eur J Nucl Med Mol Imaging. 2024 Sep 27. doi: 10.1007/s00259-024-06920-6. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39331131
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Among authors: herrmann k. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free article. Clinical Trial.
1,409 results